Status:
COMPLETED
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
Lead Sponsor:
Cambridge Health Alliance
Conditions:
COVID
Sars-CoV2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
Detailed Description
After being informed of the study and potential risks and benefits, patients meeting eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as follows: Inpatients: * N-ac...
Eligibility Criteria
Inclusion
- known or suspect COVID-19 disease AND one or more of the following influenza-like symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of breath chest pain
Exclusion
- Minors, pregnant women and people unable to provide informed consent are excluded from this study
Key Trial Info
Start Date :
September 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2021
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT04419025
Start Date
September 23 2020
End Date
May 14 2021
Last Update
May 28 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA Cambridge Hospital
Cambridge, Massachusetts, United States, 02138
2
CHA Everett Hospital
Everett, Massachusetts, United States, 02149
3
CHA Respiratory Clinic
Somerville, Massachusetts, United States, 02143
4
CHA Somerville campus
Somerville, Massachusetts, United States, 02144